Comparative study of the immunogenicity and safety of Engerix-B administered at 0, 1, 2 and 12 months and Recombivax HB administered at 0, 1, and 6 months in healthy adults
- 31 December 1995
- Vol. 13 (17) , 1665-1668
- https://doi.org/10.1016/0264-410x(95)00118-k
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Comparative study of the immunogenicity and safety of two dosing schedules of Engerix-B hepatitis B vaccine in neonatesThe Pediatric Infectious Disease Journal, 1994
- A Randomized, Controlled Trial of Interferon Alfa-2b Alone and after Prednisone Withdrawal for the Treatment of Chronic Hepatitis BNew England Journal of Medicine, 1990
- Summary of safety and efficacy data on a yeast-derived hepatitis B vaccineThe American Journal of Medicine, 1989
- Seroepidemiology of Hepatitis B virus infection in the United States 1976 to 1980The American Journal of Medicine, 1989
- Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen-positive mothersJAMA, 1989
- Yeast-recombinant hepatitis B vaccine. Efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmissionJAMA, 1987
- Hepatitis B VaccineNew England Journal of Medicine, 1980